Eric Gerd Pamer

About

Eric Gerd Pamer, MD, is the Donald F. Steiner Professor of Medicine at the University of Chicago, where he also holds positions as Professor of Microbiology and Professor of Pathology. He is actively involved in multiple committees including the Committee on Cancer Biology, the Committee on Clinical Pharmacology and Pharmacogenomics, and the Committee on Immunology. Dr. Pamer is the Director of the Duchossois Family Institute. His research focuses on host-pathogen interactions, infectious diseases, microbiology, microbiome, and microbiota. His laboratory studies interactions between pathogenic and beneficial bacteria and their mammalian hosts, utilizing genomic, proteomic, and metabolomic approaches, and employs gnotobiotic mice to test commensal consortia for their ability to enhance resistance against pathogenic bacteria. His work has identified novel mechanisms of antimicrobial resistance that can be exploited to reduce infection risks from highly antibiotic-resistant pathogens. Additionally, he has collaborated with clinical groups to investigate the microbiota's role in clinical outcomes, demonstrating that loss of microbiota diversity impacts outcomes during allogeneic hematopoietic cell transplantation and influences the risk of colitis during checkpoint blockade cancer immunotherapy. Dr. Pamer's educational background includes an MD from Case Western School of Medicine and a BA in Biology from Case Western Reserve University. His research has contributed…

Research topics

• Biology
• Microbiology
• Medicine
• Immunology
• Bioinformatics
• Internal medicine
• Gastroenterology
• Genetics
• Biochemistry
• Ecology

Selected publications

• Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

  New England Journal of Medicine · 2020 · 724 citations

  BACKGROUND: Relationships between microbiota composition and clinical outcomes after allogeneic hematopoietic-cell transplantation have been described in single-center studies. Geographic variations in the composition of human microbial communities and differences in clinical practices across institutions raise the question of whether these associations are generalizable. METHODS: The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell…

  DOI

• Functional and Genomic Variation between Human-Derived Isolates of Lachnospiraceae Reveals Inter- and Intra-Species Diversity

  Cell Host & Microbe · 2020 · 419 citations

  Senior authorCorresponding
  DOI

• Microbiome-based therapeutics

  Nature Reviews Microbiology · 2022 · 410 citations

  Senior authorCorresponding
  DOI

• Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

  Blood · 2020 · 79 citations

  We previously described clinically relevant reductions in fecal microbiota diversity in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Recipients of high-dose chemotherapy and autologous HCT (auto-HCT) incur similar antibiotic exposures and nutritional alterations. To characterize the fecal microbiota in the auto-HCT population, we analyzed 1161 fecal samples collected from 534 adult recipients of auto-HCT for lymphoma, myeloma, and amyloidosis in an observational…

  DOI

• Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure

  Nature Communications · 2022 · 71 citations

  Respiratory failure and mortality from COVID-19 result from virus- and inflammation-induced lung tissue damage. The intestinal microbiome and associated metabolites are implicated in immune responses to respiratory viral infections, however their impact on progression of severe COVID-19 remains unclear. We prospectively enrolled 71 patients with COVID-19 associated critical illness, collected fecal specimens within 3 days of medical intensive care unit admission, defined microbiome compositions…

  PublisherOA PDFDOI

Recent grants

• Project 4: Using Synthetic Immunology to Improve Activity and Specificity, and Overcome Resistance, in Cellular Therapy

  NIH · $138.0M · 1997–2025

• NIH Grant T32AI055409

  NIH · $1.1M · 2010

• Systems Biology of Microbiome-mediated Resilience to Antibiotic-resistant Pathogens

  NIH · $7.1M · 2016–2021

Frequent coauthors

• Ying Taur

  Memorial Sloan Kettering Cancer Center

  200 shared

• Marcel R.M. van den Brink

  Cornell University

  190 shared

• Ingrid M. Leiner

  140 shared

• Jonathan U. Peled

  130 shared

• Eric R. Littmann

  86 shared

• Robert R. Jenq

  84 shared

• Miguel-Ángel Perales

  80 shared

• Sergio Giralt

  Memorial Sloan Kettering Cancer Center

  72 shared

Labs

• Pamer LabPI

Education

• B.A., Biology

  Case Western Reserve University

  1977

• M.D., Medicine

  Case Western School of Medicine

  1982

• M.D., Medicine/Infectious Diseases

  University of California, San Diego

  1990

Similar researchers at University of Chicago

• Erin Greenh-70
• John A. Schneiderh-55
• Stephen G. Weberh-53